Can red light therapy be used in patients with a diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Red light therapy can potentially be used with a diagnosis of MGUS (Monoclonal Gammopathy of Undetermined Significance), but it's crucial to consult with your hematologist or oncologist before starting any new therapy, as the most recent study in 2024 1 suggests that repeated low-level red-light therapy is safe, but its effects on blood disorders or precancerous conditions like MGUS are not well-studied.

Key Considerations

  • There are no known direct contraindications between red light therapy and MGUS, but the condition requires careful monitoring, and any new treatments should be discussed with your healthcare team.
  • Red light therapy sessions typically involve exposure to red or near-infrared light for about 10-20 minutes, 3-5 times per week, but the specific duration and frequency may vary based on the device used and your individual health status.
  • It's essential to follow the manufacturer's instructions for the specific red light therapy device you're using and be aware of potential safety limits, as some devices may exceed maximum permissible exposure (MPE) limits, as reported in a 2024 study 2.

Potential Benefits and Risks

  • Red light therapy works by stimulating cellular energy production and reducing inflammation, which could theoretically be beneficial for MGUS patients, but its effects on blood disorders or precancerous conditions are unclear.
  • A 2020 study 3 found that red light therapy reduced mechanical sensitivity and neuronal cell death, and altered glial responses after spinal cord injury in rats, suggesting potential benefits for pain management.
  • However, the lack of studies on the specific use of red light therapy in MGUS patients means that potential risks and benefits are not well understood, and patients should be closely monitored by their healthcare provider.

Monitoring and Precautions

  • MGUS requires regular medical follow-ups and blood tests to monitor for progression to multiple myeloma, and any changes in your condition or new symptoms should be reported to your doctor immediately.
  • Your healthcare provider may want to monitor your blood work more closely if you decide to incorporate red light therapy into your wellness routine, especially given the potential risks and uncertainties associated with its use in MGUS patients.

References

Research

Safety of repeated low-level red-light therapy for myopia: A systematic review.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2024

Research

Red light instruments for myopia exceed safety limits.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.